セレンファーマ

Selen Pharma is a Japanese biotechnology company that specialized in the development of personalized cancer immunotherapies, specifically dendritic cell-based vaccines. The company's core technology involved pulsing a patient's own dendritic cells with the Wilms tumor protein 1 (WT1) peptide to trigger a targeted immune response against malignant cells. Its lead candidate, S-DC-01, reached Phase 3 clinical trials in Japan for the treatment of pancreatic cancer, representing a significant effort in the field of regenerative medicine. Originally established as a subsidiary of tella Inc., Selen Pharma's operations were severely impacted by the bankruptcy of its parent company in 2022, leading to the cessation of its primary clinical programs.